Improving the current medical practice for mental health disorders such as depression, is a major concern for all stakeholders.The overall costs such as social and professional disabilities, increasing suicide rates, remain under-...
ver más
31/07/2018
ELMINDA LTD
71K€
Presupuesto del proyecto: 71K€
Líder del proyecto
ELMINDA LTD
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite participación
Sin fecha límite de participación.
Financiación
concedida
El organismo H2020 notifico la concesión del proyecto
el día 2018-07-31
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto PREDICT
Duración del proyecto: 6 meses
Fecha Inicio: 2018-01-31
Fecha Fin: 2018-07-31
Líder del proyecto
ELMINDA LTD
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Improving the current medical practice for mental health disorders such as depression, is a major concern for all stakeholders.The overall costs such as social and professional disabilities, increasing suicide rates, remain under-researched and their impacts are under-recognized by key decision-makers. In light of the economic and social burden caused by major depressive disorder (MDD), there is a strong need in the EU to provide citizens with adequate diagnosis and optimized treatment options. In this framework, PREDICT represents an innovative and disruptive tool; it is an EEG integrated software-based solution for physicians, which monitors brain electrophysiological activity with the scope of supporting and optimizing treatment decisions for depressed patients. The adoption of PREDICT in psychiatric clinics will positively affect patients, clinicians and it will potentially reduce costs for health service providers and for the whole society. Innovative technologies such as non-invasive Transcranial magnetic stimulation (TMS) offer a good alternative to the conventional antidepressants drug treatment. There is clear shortage in clinical PREDICTion tools which support better informed decisions and tackle the need to personalize the patient treatment. Our solution will provide a real-time, cost-effective method to assess TMS treatment efficacy and allow higher rates of treatment response. At later stages of product development, it will be expanded to cover PREDICTion to all available anti-depressant treatments. The suggested feasibility study will assess the overall economic benefits and will support ElMindA in exploring intellectual property opportunities through IP management and updated Freedom to operate analysis. By providing an accurate, simple to use cost-effective tool, our project intends to deliver an innovative solution that can generate a strong impact on society, increasing the quality of life and life expectancy of people experiencing major depression.